| Literature DB >> 29328905 |
Gary Benson1, Günter Auerswald2, Gerry Dolan3, Anne Duffy4, Cedric Hermans5, Rolf Ljung6,7, Massimo Morfini8, Silva Zupančić Šalek9,10,11.
Abstract
Mild haemophilia is defined by factor levels between 0.05 and 0.40 IU/mL and is characterised by traumatic bleeds. Major issues associated with mild haemophilia are that it may not present for many years after birth, and that awareness, even within families, may be low. Methodological problems exist in diagnosis, such as inconsistencies in results obtained from different assays used to measure factor levels in mild haemophilia. Advances in genetic testing provide insight into diagnosis as well as the likelihood of inhibitor development, which is not uncommon in patients with mild or moderate haemophilia and can increase morbidity. The management of patients with mild haemophilia is a challenge. This review includes suggestions around formulating treatment plans for these patients, encompassing the full spectrum from clinical care of the newly diagnosed neonate to that of the ageing patient with multiple comorbidities. Management strategies consider not only the vast differences in these patients' needs, but also risks of inhibitor development and approaches to optimally engage patients.Entities:
Mesh:
Substances:
Year: 2017 PMID: 29328905 PMCID: PMC6214819 DOI: 10.2450/2017.0150-17
Source DB: PubMed Journal: Blood Transfus ISSN: 1723-2007 Impact factor: 3.443